
Bundeskartellamt has cleared plans by AMEOS Psychiatrie Holding GmbH to acquire Sana-Kliniken Ostholstein GmbH. Sana Ostholstein runs three general hospitals in Fehmarn, Eutin and Oldenburg, and a geriatric specialist clinic in Middelburg. The AMEOS group is one of the large private health care providers in Germany, Austria, and Switzerland, operating more than 95 facilities at more than 50 locations.
This merger had already been notified to the Bundeskartellamt in 2018. At that time, the Bundeskartellamt had expressed competition concerns due to AMEOS’s ties with Schön Klinik Neustadt, which is also located in Ostholstein, via a joint investor (Carlyle). Following these concerns, AMEOS withdrew the notification at the time.
Carlyle has recently sold its interest in AMEOS to another financial investor (ICG). While this investor also holds other interests in the German health care sector, it has no shares in acute care clinics in the Ostholstein district. AMEOS itself has also hardly been active in this field in Ostholstein.
Andreas Mundt, President of the Bundeskartellamt, said, “Since AMEOS has taken the competition concerns expressed by the Bundeskartellamt into account and the connection to Schön Kliniken has been terminated, the acquisition of Sana-Kliniken in Ostholstein no longer raises any competition concerns.”
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas